COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #104 of 255
8/1 Early treatment study
Bernabeu-Wittel et al., J. Gerontol. A Biol. Sci. Med. Sci., doi:10.1093/gerona/glaa192 (Peer Reviewed)
Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks
Source   PDF   Share   Tweet
Retrospective 272 nursing home residents showing significantly improved survival after establishing a treatment program including HCQ with or without lopinavir/ritonavir and with the addition of adjuvant and antimicrobial treatments depending on circumstances. Dosage details are in the supplementary appendix. Mortality relative risk is from [1].

Bernabeu-Wittel et al., 8/1/2020, retrospective, Spain, Europe, peer-reviewed, 13 authors, dosage 400mg bid day 1, 200mg bid days 2-7.
risk of death, 59.0% lower, RR 0.41, p = 0.03, treatment 189, control 83.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 255 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit